{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:58:42Z","timestamp":1783360722733,"version":"3.54.6"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Chronic pruritus is a major symptom of atopic dermatitis (AD). Its etiopathogenesis is complex, and an understanding of the driving factors of its pathogenesis allows for the development of new molecule-targeted therapies. Dupilumab, targeting and blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) molecules, has shown great efficacy in treating AD symptoms such chronic itching. We performed a retrospective observational study to evaluate possible chronic-itch-related characteristics and parameters in 356 AD patients who received dupilumab. The objective of the study was to evaluate the factors associated with the level of pruritus reported by patients at each of the 1575 detections in the form of the peak pruritus numerical rating scale (NRSpp) and sleep disturbance numerical rating scale (NRSsd). We focused on: the eczema area and severity index (EASI), dermatology life quality index (DLQI), patient-oriented eczema measure (POEMS), eosinophilia, L-lactate dehydrogenase (LDH), immunoglobulin E (IgE) and the time from the start of dupilumab therapy. NRSpp fell from 8.6 (sd 1.7) at baseline to 1.7 (sd 2.3) at 36 months and NRSsd from 7 (sd 3) to 0. Regarding the parameters that correlate with NRSpp, all the parameters analysed were significantly correlated except for eosinophils (p = 0.136). In the multivariate analysis, both considering and not considering treatment duration, the parameters were correlated (p &lt; 0.001); EASI, DLQI, POEM, and LDH significantly correlated with NRSpp (p &lt; 0.001 for each, except for LDH p = 0.003); while IgE tot lost significance (p = 0.337). Similar results were obtained for the parameters correlating with NRSsd. Our results confirm the efficacy of dupilumab on pruritus. The use of questionnaires such as DLQI and POEM is advisable in clinical practice and is adequate for assessing the impact of itching on AD. The low correlation of IgE and eosinophils, the ambiguity of LDH levels with the level of pruritus, and a poor clinical validity and unclear correlation with disease severity suggest a progressive abandonment of monitoring of these values.<\/jats:p>","DOI":"10.3390\/ph15070883","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T01:53:22Z","timestamp":1658109202000},"page":"883","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rosset","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-0322","authenticated-orcid":false,"given":"Federica","family":"Gelato","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via Cherasco 23, 10121 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11882-008-0049-z","article-title":"What causes itch in atopic dermatitis?","volume":"8","author":"Yosipovitch","year":"2008","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.iac.2016.08.007","article-title":"Itch in Atopic Dermatitis","volume":"37","author":"Furue","year":"2017","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00128071-200304090-00004","article-title":"Itch associated with skin disease: Advances in pathophysiology and emerging therapies","volume":"4","author":"Yosipovitch","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1152\/jn.90482.2008","article-title":"Separate Peripheral Pathways for Pruritus in Man","volume":"100","author":"Namer","year":"2008","journal-title":"J. Neurophysiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Srour","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"40","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Simpson","year":"2015","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e15407","DOI":"10.1111\/dth.15407","article-title":"Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis","volume":"35","author":"Miniotti","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e15115","DOI":"10.1111\/dth.15115","article-title":"Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study","volume":"34","author":"Mastorino","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1111\/jdv.16219","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: A real-life Italian tertiary centre experience","volume":"34","author":"Ribero","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: Experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"84S","DOI":"10.12788\/j.sder.2016.041","article-title":"Update on Epidemiology, Diagnosis, and Disease Course of Atopic Dermatitis","volume":"35","author":"Simpson","year":"2016","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: A placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Umehara, Y., Kiatsurayanon, C., Trujillo-Paez, J., Chieosilapatham, P., Peng, G., Yue, H., Nguyen, H., Song, P., Okumura, K., and Ogawa, H. (2021). Intractable Itch in Atopic Dermatitis: Causes and Treatments. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030229"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: A systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., and Girolomoni, G. (2021). Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines, 9.","DOI":"10.3390\/vaccines9030303"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1398-9995.2010.01995.x","article-title":"Pathophysiology and therapy of pruritus in allergic and atopic diseases","volume":"65","author":"Buddenkotte","year":"2010","journal-title":"Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.clindermatol.2018.05.011","article-title":"Patient-reported outcomes and quality of life measures in atopic dermatitis","volume":"36","author":"Vakharia","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: Psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e896","DOI":"10.1111\/jdv.17541","article-title":"Dupilumab in atopic dermatitis: Predictors of treatment outcome and time to response","volume":"35","author":"Nettis","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ijd.15183","article-title":"Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis","volume":"60","author":"Yamauchi","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-1428","article-title":"Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma","volume":"93","author":"Suga","year":"2013","journal-title":"Acta Derm. Venereol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/7\/883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:26Z","timestamp":1760140346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/7\/883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ph15070883"],"URL":"https:\/\/doi.org\/10.3390\/ph15070883","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]}}}